Bleeding-Linked Hospitalization Up With Amiodarone in A-Fib
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
TUESDAY, May 23, 2023 -- For patients with atrial fibrillation receiving apixaban or rivaroxaban, the risk of bleeding-related hospitalizations is greater during amiodarone treatment than flecainide or sotalol, according to a study published online May 22 in the Annals of Internal Medicine.
Wayne A. Ray, Ph.D., from the Vanderbilt University School of Medicine in Nashville, Tennessee, and colleagues compared risk for bleeding-related hospitalizations during treatment with amiodarone versus flecainide or sotalol in a retrospective cohort study. Data were included for 91,590 patients aged 65 years or older with atrial fibrillation who initiated use of anticoagulants and antiarrhythmic drugs: 54,977 with amiodarone and 36,613 with flecainide or sotalol.
The researchers observed an increase in the risk for bleeding-related hospitalizations with use of amiodarone (rate difference, 17.5 events per 1,000 person-years; hazard ratio, 1.44). No increase was seen in the incidence of ischemic stroke or systemic embolism. The risk of death with recent evidence of bleeding was higher than that seen for other deaths (risk difference, 9.1 versus 5.6 events per 1,000 person-years; hazard ratio, 1.66 versus 1.15). The increased incidence of bleeding-related hospitalizations was higher for rivaroxaban than for apixaban (risk difference, 28.0 versus 9.1 events per 1,000 person-years).
"These findings, consistent with pharmacokinetic data and case reports, suggest that bleeding risk should be considered in the management of rhythm control medications," the authors write.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted May 2023
Read this next
Three-Month Blanking Period After A-Fib Ablation Should Be Shortened, Researchers Say
MONDAY, April 22, 2024 -- The three-month blanking period (BP) after atrial fibrillation (AF) ablation, when recurrences are not thought to predict long-term outcome, is called...
2000-2010 to 2011-2022 Saw Increase in Lifetime Risk for A-Fib
FRIDAY, April 19, 2024 -- From 2000 to 2022, there was an increase in the lifetime risk for atrial fibrillation, according to a study published online April 17 in The...
Periodontitis May Modify Risk for Atrial Fibrillation
THURSDAY, April 11, 2024 -- Periodontitis is a risk factor for atrial fibrillation (AF), according to a study published online April 10 in the Journal of the American Heart...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.